1. Peptide Ligands Specifically Targeting HER2 Receptor and the Role Played by a Synthetic Model System of the Receptor Extracellular Domain: Hypothesized Future Perspectives
   Stefania De Luca et al, 2020, Journal of Medicinal Chemistry CrossRef
2. Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
   Haozhong Ding et al, 2021, Pharmaceutics CrossRef
3. Cyclic versus Noncyclic Chelating Scaffold for 89Zr-Labeled ZEGFR:2377 Affibody Bioconjugates Targeting Epidermal Growth Factor Receptor Overexpression
   Dominik Summer et al, 2018, Molecular Pharmaceutics CrossRef
4. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging
   null Vorobyeva et al, 2019, International Journal of Molecular Sciences CrossRef
5. Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein
   Javad Garousi et al, 2021, Pharmaceutics CrossRef
6. Novel Real-Time Proximity Assay for Characterizing Multiple Receptor Interactions on Living Cells
   Sina Bondza et al, 2017, Analytical Chemistry CrossRef
7. Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
   Mohamed Altai et al, 2018, Cells CrossRef
8. Physiological Considerations for Modeling in vivo Antibody-Target Interactions
   Tyler Dunlap et al, 2022, Frontiers in Pharmacology CrossRef